Introduction
============

Suicidal behavior (SB) is a complex phenotype with biological, genetic, and environmental risk factors involved.[@b1-ndt-14-2485],[@b2-ndt-14-2485] Several arguments show that psychiatric disturbances are major contributing factors in SB; however, genetic predisposition has been strongly considered to be a contributory factor in SB,[@b3-ndt-14-2485],[@b4-ndt-14-2485] and evidence indicates that SB is modulated by a number of gene variants.[@b2-ndt-14-2485],[@b4-ndt-14-2485] The majority of investigations have focused on genes that codify proteins of different neurotransmitter systems, such as dopamine transporter, serotonin transporter, the two isoforms of tryptophan hydroxylase, the serotonin receptors family, and catechol-*O*-methyltransferase (*COMT*).[@b2-ndt-14-2485],[@b5-ndt-14-2485],[@b6-ndt-14-2485]

The *COMT* gene has been repeatedly explored in SB. COMT is one of the major enzymes involved in catecholamine degradation. Its gene is located on chromosome 22q11.1-11.2, and more than 4,000 polymorphisms have been identified (<https://www.genecards.org/>).[@b7-ndt-14-2485]--[@b12-ndt-14-2485] Human *COMT* contains a common functional polymorphism, G.A substitution in exon 4, which changes the amino acid at codon 108 (Val108Met) in soluble COMT or position 158 (Val158Met) in the membrane-bound COMT protein.[@b13-ndt-14-2485]--[@b16-ndt-14-2485] It has been observed that the COMT enzyme that contains valine has a relatively higher activity than the COMT enzyme that contains methionine.[@b17-ndt-14-2485]--[@b21-ndt-14-2485] This allele seems to be codominant with heterozygote enzyme activity following midway between the homozygous alleles.[@b13-ndt-14-2485]--[@b16-ndt-14-2485]

During the last few decades, many studies have analyzed the role of *COMT* and SB, with contradictory results. For instance, Ohara et al[@b22-ndt-14-2485] reported, in 1996, that there was no association between *COMT* and suicide, while the group of Pivac et al[@b23-ndt-14-2485] reported, in 2011, an association between *COMT* Val/Val genotype and suicide in nonalcoholic suicide completers. In addition, other studies have shown that the genotype that encodes the more active COMT enzyme (Val/Val) is more frequent in suicide attempters than in healthy subjects used as controls.[@b24-ndt-14-2485] However, other reports have found no overall difference in allele/genotype frequency distribution between cases and controls but have found that the Met allele was more frequent among violent suicide attempters.[@b25-ndt-14-2485] Several studies suggest that the Val108/158Met polymorphism of the *COMT* gene plays a role in numerous psychiatric disorders[@b26-ndt-14-2485]--[@b32-ndt-14-2485] but have not obtained conclusive results about a relationship between SB and the *COMT* gene. Therefore, meta-analytic techniques that summarize all data available and assess sample size effects as well as publication bias can provide results with a major statistical power.[@b7-ndt-14-2485],[@b14-ndt-14-2485],[@b33-ndt-14-2485]--[@b36-ndt-14-2485] Up to 2011, three meta-analyses had evaluated the association between the *COMT* gene and suicide;[@b7-ndt-14-2485],[@b33-ndt-14-2485],[@b37-ndt-14-2485] however, five more recently published studies have contributed more information to understand the complexity of the genetic background of SB. Given the importance of the *COMT* gene in SB, we performed an updated meta-analysis and systematic review to further explore the hypothesis of the genetic predisposition of the Val108/158Met *COMT* polymorphism in SB.

Materials and methods
=====================

The systematic review and meta-analysis were conducted in light of the statement of Preferred Reporting Items for Systematic Reviews and Meta-Analyses. This study had been previously registered in PROSPERO (PROSPERO 2017 CRD42017070229). As no human participants or animals had been recruited, ethical approval was not required.

Literature search strategy
--------------------------

To identify relevant articles, we performed an online search through PubMed and Web of Science, up to March 2017, using as keywords "*COMT* gene AND suicide," "rs4680 AND suicide," and "Val108/158Met AND suicide."

Inclusion/exclusion criteria
----------------------------

Relevant studies had to fulfill the following criteria: 1) studies with a case-control or cohort design; 2) studies evaluating the association between rs4680 *COMT* variant and suicide; 3) studies published in English and in peer-reviewed journals; 4) the genotype frequency distribution had to be cited or could be calculated; and 5) studies containing sufficient information to calculate ORs. The articles were excluded when 1) they were found to contain overlapping data, 2) the number of null and wild genotypes could not be ascertained, and 3) family members had been included in the case group because their analyses were based on linkage consideration.

Data extraction
---------------

The general information extracted from the articles included the following: first author, year of publication, country (area) of origin, study design, source of control groups (case-control studies), sample size, genotyping methods, diagnostics, methods used for the diagnostics matching variables, genotype and allele frequency distributions, and outcome findings. This key information was extracted in consensus by Hernández-Díaz and González-Castro.

Statistical analysis
--------------------

The meta-analysis was carried out with the use of the Comprehensive Meta-Analysis Version 2.0 software (Biostat Inc., Englewood, NJ, USA). The analysis was performed using five genetic models (allele, dominant, recessive, homozygous, and heterozygous). For each model, the OR and 95% CI were calculated, and the results are presented as the random effects model of meta-analysis. The presence of heterogeneity was indicated when the *P*-value of the *Q* test \<0.1 or *I*^2^\>50%. The OR estimates for each study were used to analyze the fixed effects model (the Mantel--Haenszel method) when there was no evidence of statistical heterogeneity. Otherwise, the random effects model (the DerSimonian and Laird method) was considered. The Galbraith plot and sensitivity analysis were used to search for published studies with heterogeneity, and the meta-analysis was performed again after these published studies were excluded. The *χ*^2^ test was used to define whether the gene frequency distribution was in Hardy Weinberg Equilibrium (HWE); the studies with a *P*\<0.5 were considered out of the HWE; therefore, they were excluded from the meta-analysis. Subgroup analyses based on location and ethnicity (Asian and European), gender (males and females), and individuals with suicide attempt (SA) were also completed. Finally, a meta-regression based on age was performed.

The power of the study was calculated as previously reported elsewhere.[@b38-ndt-14-2485] Using an effect size *d*=0.20 and 14 studies with 140 patients per group, we obtained a power of 0.99.

Quality assessment
------------------

The quality assessment of each study was performed using the Newcastle--Ottawa Quality Assessment Scale (NOS). A NOS \>6 was considered a high-quality study. Any disparity about the NOS scores was resolved in consultation with a third reviewer.

Publication bias and sensitivity analyses
-----------------------------------------

In addition, sensitivity and publication bias of the studies were evaluated. The sensitivity analysis was done by eliminating one study at a time. Begg's test and Egger's test were used to evaluate publication bias of the included studies; *P*\<0.5 was considered statistically significant.

Results
=======

Studies included
----------------

Ninety-three studies were first identified; after reviewing titles, abstracts, and compliance with the inclusion criteria, 17 studies were enrolled in this meta-analysis. A flowchart describing the inclusion/exclusion of the individual studies is displayed as [Figure 1](#f1-ndt-14-2485){ref-type="fig"}. The included studies were published between 1998 and 2016. Of these 17 studies, six evaluated European populations, six evaluated Asian descendants, three used a mixed population, and two evaluated American individuals. The genotype and frequency distributions are presented in [Table 1](#t1-ndt-14-2485){ref-type="table"}. The studies of Schosser et al,[@b32-ndt-14-2485] Baud et al,[@b24-ndt-14-2485] and Sun et al,[@b36-ndt-14-2485] were excluded from all the analyses because their control groups presented a HWE *P*-value \<0.05.

Overall findings
----------------

In the overall population, after discarding the studies of Nedic et al,[@b11-ndt-14-2485] and Ono et al,[@b21-ndt-14-2485] (because the sensitivity and heterogeneity analyses indicated that they favored the presence of heterogeneity between studies), the association between the Val108/158Met *COMT* polymorphism and susceptibility to suicide was evaluated in 3,282 cases and 3,774 controls. No significant association was observed in any of the comparisons: allele model (OR =1.05; 95% CI =0.95--1.18; *Z P*-value =0.29), homozygous (OR =1.15, 95% CI =0.94--1.42, *Z P*-value =0.16), heterozygous (OR =1.06, 95% CI =0.91--1.24, *Z P*-value =0.43), dominant (OR =1.15, 95% CI =0.97--1.37, *Z P*-value =0.10), and recessive model (OR =1.10, 95% CI =0.95--1.28, *Z P*-value =0.18). The Egger's test and Begg's funnel did not evidence publication bias; [Figure 1](#f1-ndt-14-2485){ref-type="fig"}. Our results are presented in [Table 2](#t2-ndt-14-2485){ref-type="table"}.

Regarding the meta-regression based on age, the overall population analysis revealed a point estimate slope of 0.0183 and a *P*-value of 0.222 ([Figure 2](#f2-ndt-14-2485){ref-type="fig"}).

Subgroup analysis
-----------------

### Asian populations

Five studies were included to investigate the association between the Val108/158Met *COMT* polymorphism and SB in Asian populations. We used allelic, homozygous, heterozygous, dominant, and recessive models and did not find any association; however, when we discarded the studies that favored heterogeneity, we found a slight association in the allelic (OR =1.25, 95% CI =1.04--1.51, *Z P*-value =0.01) and recessive (OR =1.32, 95% CI =1.03--1.68, *Z P*-value =0.02) models; [Figure 3](#f3-ndt-14-2485){ref-type="fig"} and [Table 2](#t2-ndt-14-2485){ref-type="table"}.

### European populations

Subsequently, using five articles, we performed an analysis of European populations. In the absence of heterogeneity, no statistical association was observed in any of the models used: allele (OR =1.00; 95% CI =0.86--1.17; *Z P*-value =0.95), homozygous (OR =1.01, 95% CI =0.74--1.37, *Z P*-value =0.93), heterozygous (OR =0.86, 95% CI =0.67--1.11, *Z P*-value =0.25), dominant (OR =1.06, 95% CI =0.81--1.40, *Z P*-value =0.64), and recessive (OR =0.94, 95% CI =0.73--1.21, *Z P*-value =0.65) models; [Figure 1](#f1-ndt-14-2485){ref-type="fig"} and [Table 2](#t2-ndt-14-2485){ref-type="table"}.

### Suicide attempters

Finally, to better comprehend the role of the *COMT*108/158 polymorphism, we performed a subgroup analysis using 11 studies that had evaluated suicide attempters. We still found the same negative results, even when we excluded one study that supported heterogeneity: allelic (OR =1.11; 95% CI =0.99--1.23; *Z P*-value =0.05), homozygous (OR =1.22; 95% CI =0.97--1.55; *Z P*-value =0.08), heterozygous (OR =1.03; 95% CI =0.86--1.23; *Z P*-value =0.71), dominant (OR =1.19; 95% CI =0.98--1.44; *Z P*-value =0.07), and recessive (OR =1.12; 95% CI =0.96--1.31; *Z P*-value =0.13) models; [Figure 3](#f3-ndt-14-2485){ref-type="fig"} and [Table 2](#t2-ndt-14-2485){ref-type="table"}.

### Male group analysis

Because of the possible influence that gender could have over the psychopathology of suicide, we evaluated the role of the *COMT* polymorphism in males. The analysis revealed an association when heterogeneity was absent in the allelic (OR =1.29; 95% CI =1.04--1.60; *Z P*-value =0.01), homozygous (OR =1.54; 95% CI =1.04--2.28; *Z P*-value =0.02), heterozygous (OR =1.67; 95% CI =1.17--2.38; *Z P*-value =0.001), and dominant (OR =1.66; 95% CI =1.18--2.31; *Z P*-value =0.001) models; [Table 2](#t2-ndt-14-2485){ref-type="table"} and [Figure 4](#f4-ndt-14-2485){ref-type="fig"}.

### Female group analysis

Similarly, we explored the involvement of the *COMT* gene variants in suicide in females. Here too, we found an association when heterogeneity was absent in the allelic (OR =0.74; 95% CI =0.59--0.92; *Z P*-value =0.001), homozygous (OR =0.57; 95% CI =0.37--0.87; *Z P*-value =0.01), heterozygous (OR =0.64; 95% CI =0.43--0.95; *Z P*-value =0.02), dominant (OR =0.60; 95% CI =0.41--0.88; *Z P*-value =0.001), and recessive (OR =0.71; 95% CI =0.51--0.98; *Z P*-value =0.03) models; [Table 2](#t2-ndt-14-2485){ref-type="table"} and [Figure 4](#f4-ndt-14-2485){ref-type="fig"}.

### Sensitivity analysis

We conducted a sensitivity analysis to evaluate the stability of our results by removing each study at a time. However, no obvious changes were observed, and this confirmed that our results were stable under the five genetic models for the *COMT* Val108/158Met polymorphism.

Discussion
==========

Some studies support the idea that there are neurobiological and genetic risks to developing SB, but the results have been inconsistent. The inconclusive results might be due to the use of small samples and differences in ethnicity.[@b13-ndt-14-2485],[@b39-ndt-14-2485] Therefore, our aim was to further understand the effect of the *COMT* polymorphism in healthy individuals and suicide attempters by undertaking a systematic review and an updated meta-analysis. The current meta-analysis investigated the effect of the *COMT* Val108/158Met polymorphism in SB in global and subgroup analyses divided into ethnicities (Asians and Europeans), suicide attempters, and gender.

The global analysis showed no effect of the *COMT* polymorphism and SB in the overall population (using 14 high-quality studies); even though we used five different models, we did not observe any statistical association. On the contrary, in 2007, a meta-analysis that evaluated six studies showed a significant association between the *COMT* Val108/158Met polymorphism and SB; however, when one study at a time was removed from the analysis, the relationship between *COMT* and SB was no longer significant.[@b14-ndt-14-2485]

Furthermore, when we divided the populations by location and ethnicity (Asians and Europeans), we observed an association between the Val108/158 polymorphism and SB in Asian individuals, but not in Europeans; however, it is noteworthy that statistical significance was seen only after we excluded heterogeneity and only after three studies remained; therefore, this sample size was too small to give conclusive results. We therefore recommend that more studies be undertaken in order to reach a conclusion about this relationship. The discrepancy observed among the outcomes can be explained as follows: the frequency distribution of the Val and Met alleles might be dependent on ethnicity, genetic architecture, as well as the combination of behavioral and environmental risk factors, assignment of a higher or lower risk of developing SB to a particular location or sample.[@b17-ndt-14-2485],[@b25-ndt-14-2485]

Furthermore, we performed, with the five models previously indicated, another subanalysis using researches that studied only suicide attempters and observed no association. However, it has been seen that the etiology of SB is multi-factorial, including biological and genetic factors that differ in each particular SB (risk of suicide, suicide ideation, SA, or completed suicide); therefore, to reach definitive conclusions, it is necessary to take this multifactorial characteristic into consideration.[@b14-ndt-14-2485],[@b40-ndt-14-2485]

The negative association we observed in the global analysis agrees with the meta-analyses by Tovilla-Zárate et al[@b33-ndt-14-2485] and Calati et al,[@b7-ndt-14-2485] who also obtained negative results in the pooled ORs in the overall populations. On the other hand, the study of Sadeghiyeh et al,[@b41-ndt-14-2485] published in 2017, showed that the *COMT* 158G/A (COMT Val158Met) polymorphism was associated with suicide susceptibility only in females.[@b7-ndt-14-2485],[@b14-ndt-14-2485],[@b33-ndt-14-2485] Following this sense, we performed an analysis by gender; the evaluation of males using the five genetic models proposed previously revealed that Val could be a risk factor for suicide in males. Regarding the group of females, we observed a protective effect of the Val allele of *COMT* polymorphism, which is similar to the findings observed by Sadeghiyeh et al,[@b41-ndt-14-2485] namely, a risk effect of the Met allele in homozygous and recessive models in the female group. However, we recommend increasing the sample size in features studies in order to increase the power to detect small effects of the polymorphism.

We emphasize that the main strength of our study in comparison with previous meta-analyses published is the number of cases and controls included. Kia-Keting et al[@b14-ndt-14-2485] used 519 cases and 933 controls, Calati et al,[@b7-ndt-14-2485] 1,324 cases and 1,415 controls, and Tovilla-Zárate et al,[@b33-ndt-14-2485] 2,723 cases and 1,886 controls. An additional meta-analysis by Sadeghiyeh et al[@b41-ndt-14-2485] involved 2,353 suicide attempters and 2,593 controls. Meanwhile, we compared 3,282 cases and 3,774 controls. Therefore, our study has more power to detect the small effects of the polymorphism.

Our study has some limitations. First, despite the sample size we used (a large number of cases and controls), our sample is not as large as the ones evaluated in other reports that have studied psychiatric disorders such as schizophrenia or bipolar disorder.[@b42-ndt-14-2485]--[@b44-ndt-14-2485] Second, we did not analyze the endophenotypes of SB. Hence, because of the available data, we could evaluate only SA, apart from SB. This is an important limitation because it has been reported that SA, suicide ideation, and death by suicide could have differences in the etiology. Third, we did not analyze environmental or biological factors that influence SB, although analyses of all variants should be performed.[@b21-ndt-14-2485],[@b45-ndt-14-2485]

Conclusion
==========

To sum up, our outcomes revealed a possible association of the *COMT* Val108/158 polymorphism with SB. In males, *COMT* Val108/158 increased the risk of SB, whereas in females, *COMT* Val108/158 exhibited a protective factor against SB. Also, *COMT* Val108/158 could be a risk factor in Asian individuals. Because of the limitation of the study, we recommend that more studies be undertaken using larger samples.
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###### 

Procedures and data analysis.

**Notes:** (**A**) Flowchart showing study inclusion and exclusion details. (**B**) Forest plot of a homozygous model in the overall population. (**C**) Begg's funnel plot analysis of publication bias in homozygous models in the overall population. (**D**) Forest plot of a dominant model in European populations.
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![Meta-regression analysis based on mean age.](ndt-14-2485Fig2){#f2-ndt-14-2485}

![Data analysis.\
**Notes:** (**A**) Forest plot of allelic model in Asian populations. (**B**) Forest plot of the recessive model in Asian populations. (**C**) Forest plot of the heterozygous model in suicide attempters. (**D**) Begg's funnel plot analysis of publication bias in the heterozygous model in suicide attempters.](ndt-14-2485Fig3){#f3-ndt-14-2485}

![Forest plot in the (**A**) male group in the allelic model, (**B**) male group in the homozygous model, (**C**) female group in the dominant model, (**D**) female group in the recessive model.](ndt-14-2485Fig4){#f4-ndt-14-2485}

###### 

Systematic review of the genetic association of Val66Met and SB, characteristics of the studies included

  First author                                   Location                     Diagnosis instrument   SB cases   Number of   Mean age   Male/female   Cases    Controls   HWE       NOS                                                
  ---------------------------------------------- ---------------------------- ---------------------- ---------- ----------- ---------- ------------- -------- ---------- --------- ----- ----- ----- ----- ----- ---- ------ -------- ---
  Ohara et al,[@b20-ndt-14-2485] 1998            Japan                        DSM-IV                 SA         115         135        38.5          --       60/55      --        2     7     3     58    59    18   0.54   0.62     4
  Nolan et al,[@b12-ndt-14-2485] 2000            USA, Finland                 DSM-IV, DSM-III-R      SA         148         --         42.35         --       42.35      --        44    66    38    --    --    --   --     --       4
  Russ et al,[@b31-ndt-14-2485] 2000             USA                          DSM-IV                 SI         51          51         38            41       32/19      28/23     12    28    9     16    26    7    0.39   0.56     8
  Liou et al,[@b45-ndt-14-2485] 2001             Taiwan                       DSM-IV                 SA         62          188        36.7          38.6     26/36      97/91     36    23    3     98    79    11   0.77   0.45     5
  Rujescu et al,[@b25-ndt-14-2485] 2003          Germany                      DSM-IV                 SA         149         328        40            46       53/96      149/179   35    69    45    78    167   83   0.41   0.82     8
  de Luca et al,[@b26-ndt-14-2485] 2005          Canada                       SCID I                 SA         336         --         35.36         --       128/208    --        --    --    --    --    --    --   --     --       4
  Ono et al,[@b21-ndt-14-2485] 2004              Japan                                               SC         163         169        47.9          47.115   112/51     114/55    68    79    16    90    61    18   0.38   0.13     8
  de Luca et al,[@b13-ndt-14-2485] 2006          Canada                       SCID I                 SA         92          178        42.6          40.6     68/24      129/49    --    --    --    --    --    --   --     --       4
  Baud et al,[@b24-ndt-14-2485] 2007             Switzerland, France          STAXI                  SA         427         185        38.7          46.08    125/302    130/55    124   218   85    34    107   44   0.55   0.03\*   8
  Zalsman et al,[@b47-ndt-14-2485] 2008          USA                          DSM-IV axis-I and II   SA         486         119        41.6          41.2     209/277    78/41     27    67    25    34    114   53   0.20   0.05     5
  Perroud et al,[@b29-ndt-14-2485] 2010          Switzerland, France          DIGS and MINI          SA         875         --         --            --       256/619    --        252   387   183   --    --    --   --     --       4
  Nedic et al,[@b11-ndt-14-2485] 2011            Croatia                      DSM-IV                 --         82          311        50.465        50.74    59/23      253/58    9     38    35    76    170   65   0.78   0.09     7
  Pivac et al,[@b23-ndt-14-2485] 2011            Slovenia                     --                     SA         356         198        48.9          47.1     --         --        78    197   81    45    97    56   0.05   0.88     7
  Tovilla-Zárate et al,[@b33-ndt-14-2485] 2011   Mexico                       DSM-IV axis-I and II   SA         105         236        30.5          34.5     55/50      132/104   34    58    13    80    112   44   0.15   0.68     6
  Calati et al,[@b7-ndt-14-2485] 2011            Germany                      SCID I and SCID II     SA         111         289        39.3          45.2     43/68      123/166   23    56    19    79    144   66   0.22   0.98     7
  Lee and Him,[@b27-ndt-14-2485] 2011            Korea                        DSM-IV                 SA         197         170        33.5          36.2     70/127     85/85     94    85    18    69    85    16   0.84   0.23     7
  Schosser et al,[@b32-ndt-14-2485] 2012                                      MINI and HAM-D         SI/SA      68          150        50.75         --       68/182     --        20    33    15    29    93    29   0.81   0.005    7
  Du et al,[@b39-ndt-14-2485] 2014               Hungary                      DSM-IV                 SC         49          72         64.5          48.915   35/14      46/26     16    19    14    22    30    20   0.15   0.16     8
  Chen et al,[@b8-ndt-14-2485] 2014              Taiwan                       DSM-IV                 SA         187         386        32.4          34.3     11/176     168/218   100   78    9     179   170   37   0.25   0.81     6
  Pasi et al,[@b28-ndt-14-2485] 2015             India                        DSM-IV and C-SSRS      SA         25          --         --            --       20:05      --        13    23    4     --    --    --   --     --       4
  Sun et al,[@b36-ndt-14-2485] 2016              People's Republic of China   DSM-IV-TR axis-I       SA         369         369        44.1          43.9     117/252    117/252   218   129   22    193   161   15   0.66   0.005    7
  Antypa et al,[@b46-ndt-14-2485] 2016           Belgium                      DSM-IV                 SA         213         240        45.99         48.88    63/150     148/192   32    44    23    38    69    39   0.31   0.51     7

**Notes:** Data not available is indicated with "--". Statistical significance is indicated with "\*".

**Abbreviations:** SB, suicidal behavior; V-V, Val-Val; V-M, Val-Met; M-M, Met-Met; DSM, Diagnostic and Statistical Manual of Mental Disorders; SCID, Structured Clinical Interview for DSM-IV; STAXI, State-Trait Anger Expression Inventory; DIGS, Diagnostic Interview for Genetic Studies; HAM-D, Hamilton Depression Rating Scale; C-SSRS: Columbia-Suicide Severity Rating Scale.

###### 

Meta-analysis results comparing inherence models between cases and controls

  Model                      Number of studies   Heterogeneity   Random effects, OR (CI 95%)   *Z P*-value   *I*^2^   *Q* test *P*-value   Egger's test *P*-value
  -------------------------- ------------------- --------------- ----------------------------- ------------- -------- -------------------- ------------------------
  **Overall population**                                                                                                                   
  Allelic                    14                  Large           0.98 (0.84--1.14)             0.85          59.84    0.00                 0.12
                             13                  Absent          1.05 (0.95--1.18)             0.29          19.94    0.24                 0.13
  Homozygous                 14                  Large           1.01 (0.74--1.37)             0.93          52.07    0.01                 0.33
                             13                  Absent          1.15 (0.94--1.42)             0.16          0.00     0.46                 0.31
  Heterozygous               14                  Moderate        0.96 (0.80--1.15)             0.68          29.48    0.14                 0.18
                             12                  Absent          1.06 (0.91--1.24)             0.43          0.00     0.52                 0.12
  Dominant                   14                  Large           1.03 (0.79--1.34)             0.80          53.88    0.00                 0.97
                             13                  Absent          1.15 (0.97--1.37)             0.10          0.00     0.60                 0.62
  Recessive                  14                  Moderate        0.97 (0.80--1.18)             0.80          43.70    0.04                 0.08
                             12                  Absent          1.10 (0.95--1.28)             0.18          0.00     0.49                 0.48
  **Asian populations**                                                                                                                    
  Allelic                    5                   Large           1.02 (0.77--1.35)             0.86          62.20    0.03                 0.27
                             3                   Absent          **1.25 (1.04--1.51)**         **0.01**      0.00     0.83                 0.65
  Homozygous                 5                   Moderate        1.14 (0.65--2.02)             0.63          42.90    0.13                 0.34
                             4                   Absent          1.32 (0.84--2.05)             0.21          11.62    0.33                 0.92
  Heterozygous               5                   Large           0.98 (0.65--1.46)             0.92          63.99    0.02                 0.42
                             4                   Absent          1.22 (0.93--1.60)             0.14          9.05     0.34                 0.14
  Dominant                   5                   Absent          1.20 (0.81--1.78)             0.35          3.37     0.38                 0.43
  Recessive                  5                   Large           1.01 (0.68--1.50)             0.95          66.03    0.01                 0.35
                             3                   Absent          **1.32 (1.03--1.68)**         **0.02**      0.00     0.99                 0.30
  **European populations**                                                                                                                 
  Allelic                    5                   Large           0.86 (0.65--1.15)             0.32          72.72    0.00                 0.58
                             4                   Absent          1.00 (0.86--1.17)             0.95          0.00     0.77                 0.89
  Homozygous                 5                   Large           0.76 (0.44--1.31)             0.33          69.43    0.01                 0.42
                             4                   Absent          1.01 (0.74--1.37)             0.93          0.00     0.80                 0.93
  Heterozygous               5                   Absent          0.86 (0.67--1.11)             0.25          0.00     0.55                 0.68
  Dominant                   5                   Large           0.84 (0.52--1.38)             0.50          77.60    0.00                 0.79
                             4                   Absent          1.06 (0.81--1.40)             0.64          15.75    0.31                 0.89
  Recessive                  5                   Moderate        0.84 (0.62--1.12)             0.24          29.24    0.22                 0.38
                             4                   Absent          0.94 (0.73--1.21)             0.65          0.00     0.92                 0.73
  **Suicide attempters**                                                                                                                   
  Allelic                    11                  Large           1.01 (0.85--1.21)             0.84          65.25    0.00                 0.26
                             10                  Absent          1.11 (0.99--1.23)             0.05          7.35     0.37                 0.22
  Homozygous                 11                  Large           1.05 (0.73--1.51)             0.78          61.35    0.00                 0.50
                             10                  Absent          1.22 (0.97--1.55)             0.08          6.16     0.38                 0.64
  Heterozygous               11                  Absent          1.03 (0.86--1.23)             0.71          18.37    0.26                 0.07
  Dominant                   11                  Large           1.05 (0.77--1.44)             0.74          64.00    0.00                 0.84
                             10                  Absent          1.19 (0.98--1.44)             0.07          1.57     0.42                 0.99
  Recessive                  11                  Moderate        1.04 (0.84--1.27)             0.69          41.02    0.07                 0.03
                             10                  Absent          1.12 (0.96--1.31)             0.13          0.73     0.43                 0.10
  **Males**                                                                                                                                
  Allelic                    7                   Large           1.00 (0.69--1.43)             0.99          79.31    0.00                 0.83
                             5                   Absent          **1.29 (1.04--1.60)**         **0.01**      16.96    0.30                 0.74
  Homozygous                 7                   Large           1.07 (0.54--2.13)             0.83          69.29    0.00                 0.65
                             6                   Absent          **1.54 (1.04--2.28)**         **0.02**      0.00     0.61                 0.50
  Heterozygous               7                   Large           1.20 (0.64--2.27)             0.55          71.69    0.00                 0.84
                             6                   Absent          **1.67 (1.17--2.38)**         **0.00**      0.00     0.52                 0.51
  Dominant                   7                   Large           1.17 (0.60--2.24)             0.63          76.26    0.00                 0.84
                             6                   Absent          **1.66 (1.18--2.31)**         **0.00**      0.00     0.76                 0.32
  Recessive                  7                   Large           0.91 (0.56--1.48)             0.71          76.07    0.00                 0.63
                             4                   Absent          1.04 (0.70--1.53)             0.83          24.20    0.23                 0.52
  **Females**                                                                                                                              
  Allelic                    7                   Moderate        0.83 (0.66--1.03)             0.09          28.30    0.21                 0.02
                             6                   Absent          **0.74 (0.59--0.92)**         **0.00**      0.00     0.70                 0.26
  Homozygous                 7                   Absent          **0.57 (0.37--0.87)**         **0.01**      0.00     0.86                 0.54
  Heterozygous               7                   Absent          **0.64 (0.43--0.95)**         **0.02**      0.00     0.48                 0.88
  Dominant                   7                   Absent          **0.60 (0.41--0.88)**         **0.00**      0.00     0.67                 0.92
  Recessive                  7                   Absent          0.86 (0.63--1.18)             0.36          28.65    0.21                 0.03
                             6                   Absent          **0.71 (0.51--0.98)**         **0.03**      0.00     0.93                 0.33

**Note:** The data in bold means association.
